Headlines

Novo CEO says its bid for Metsera is higher

Published by Global Banking & Finance Review

Posted on November 6, 2025

1 min read

· Last updated: January 21, 2026

Add as preferred source on Google
Novo CEO says its bid for Metsera is higher
Global Banking & Finance Awards 2026 — Call for Entries

NEW YORK (Reuters) -Novo Nordisk CEO Mike Doustdar said during a White House event on Thursday that the company's bid for obesity biotech Metsera is higher than the one from rival Pfizer Inc., which

Novo CEO says its bid for Metsera is higher

NEW YORK (Reuters) -Novo Nordisk CEO Mike Doustdar said during a White House event on Thursday that the company's bid for obesity biotech Metsera is higher than the one from rival Pfizer Inc., which has sued both Metsera and Novo over the terms of their rival deal. 

"As of today, our bid is higher, and our message to Pfizer is that if they would like to buy the company, then put your hand in the pocket and bid higher," Doustdar said.

(Reporting by Bhargav Acharya)

Key Takeaways

  • Novo Nordisk's bid for Metsera is higher than Pfizer's.
  • Pfizer has initiated a lawsuit over the acquisition terms.
  • Novo CEO challenges Pfizer to increase their bid.
  • The acquisition involves obesity biotech Metsera.
  • The announcement was made at a White House event.

Frequently Asked Questions

What is a merger?
A merger is a business combination where two companies join to form a single entity, often to increase market share, reduce competition, or achieve synergies.
What is an acquisition?
An acquisition occurs when one company purchases another company, gaining control over its assets and operations, often to expand its market presence or capabilities.
What is a bid in finance?
A bid in finance refers to an offer made by an investor or company to purchase a security or asset at a specified price.

Tags

Related Articles

More from Headlines

Explore more articles in the Headlines category